GMED GLOBUS MEDICAL INC Insider Trading

Director David D Davidar sold 25,000 shares of GMED at $80.76 for $2.0M on 2026-06-05, retaining 510.2K shares.

David D Davidar, a GMED director, sold 25,000 shares at $80.76, reducing his non-derivative holdings from 535.2K to 510.2K shares (a -4.7% decrease). GMED's fundamentals remain solid with revenue of $759.9M and net income of $124.3M in the latest quarter, alongside annual revenue growth of +16.6%. Davidar maintains a substantial residual position of 510.2K shares post-transaction, indicating continued significant direct investment in the company. His cross-ticker track record shows 9 prior sells; however, none of his prior same-ticker transactions at GMED have yet reached measurable 90-day outcome points, limiting inference about his timing accuracy at this specific stock. The sale appears consistent with a partial reduction rather than a material change in conviction.

EVP/GC Kelly Huller sold 20,000 shares of GMED at $94.50 on 2026-02-25 under 10b5-1 plan; position reduced to zero

Huller Kelly, Executive Vice President, General Counsel, and Corporate Secretary, completed a sale of 20,000 shares (20.0K shares) for $1,890,000.00 ($1.9M) under a pre-arranged 10b5-1 trading plan. The transaction eliminated her entire stake, reducing holdings from 20,000 shares (20.0K shares) to 0 shares (representing a -100.0% reduction). Because this sale was scheduled under a 10b5-1 plan rather than discretionary, it reflects pre-established trading instructions rather than a real-time decision driven by current market conditions or sentiment. The complete exit of her shareholding merits attention as a baseline observation, though the mechanics of the plan constrain what can be inferred about her contemporaneous views.

CFO Kyle Kline sells entire 18,542-share GMED stake ($1.7M) via pre-arranged 10b5-1 plan on 2025-12-01

Kyle Kline, Senior Vice President and CFO of Globus Medical, completed a sale of 18,542 shares at $90.00, reducing his holdings to zero shares. The transaction was executed under a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. A complete liquidation of an executive's position warrants investor attention, particularly for a financial officer, though the Rule 10b5-1 structure limits inference about current decision-making or conviction.

Director David Davidar sold 25,000 GMED shares at $86.00 for $2.2M; strong prior timing at same ticker with 4 of 5 sells well-timed at 90-day mark.

Director David Davidar sold 25,000 shares (25.0K shares) of GLOBUS MEDICAL INC (GMED) at $86.00 on 2025-11-12, reducing holdings by 4.6% to 516,275 shares. The stock has appreciated significantly over 30 and 90 days (+44.6% and +38.7% respectively), trading near its 52-week high. Notably, his prior trades at GMED show a strong timing pattern: 4 of 5 prior sells were well-timed at the 90-day mark, with three consecutive sales on 2024-11-21 and 2024-11-22 each followed by -2.8% and -1.0% to -1.1% 90-day returns. This sell occurs when the stock is positioned in the upper portion of its annual trading range and after a sustained multi-month rally, consistent with his demonstrated pattern of selling into strength at this particular ticker.

Director Stephen T Zarrilli sells entire stake of 25.0K shares at $84.29, exiting GMED position amid 60.6% annual revenue growth and 26.50 P/E

Director Zarrilli liquidated his entire holding of 25,000 shares (-100.0% vs pre-transaction holdings) for $2,107,257.50 on 2025-11-11, exiting a position he held through a period of significant stock appreciation. The sale occurred at $84.29 per share, within 9.7% of the 52-week high of $93.32, while the company reports robust fundamentals: annual revenue growth of +60.6%, net income of $119.0M, and a market cap of $11.2B. The timing coincides with substantial recent momentum—the stock has risen 44.6% over 30 days and 38.7% over 90 days. The complete exit is noteworthy; insider directors often retain some stake to signal continued alignment with shareholders.

GMED COO/then-CFO Pfeil sold all 14,167 shares (14.2K) for $1,250,770.39 via scheduled 10b5-1 plan

Pfeil Keith W, who was COO and CFO at the time of filing, sold all 14,167 shares (14.2K shares) on 2025-01-10 across 2 separate sales at $88.17 and $89.17 per share for total proceeds of $1,250,770.39, reducing his post-transaction holdings to 0 shares. This complete liquidation was executed under a pre-arranged 10b5-1 trading plan, indicating the sales were scheduled and not discretionary. The blended average sale price was $88.29. As a scheduled transaction under a 10b5-1 plan, this sale reflects a predetermined trading arrangement rather than a real-time discretionary decision, so no timing-based inference about conviction or market view should be drawn from the execution itself.

Scavilla Daniel T, then-CEO, sold entire 130,000 share position (130.0K shares) at $85.00 for $11.0M on 2024-11-21 via 10b5-1 plan.

Scavilla Daniel T, who was CEO at the time, executed a complete liquidation of his equity stake, selling 130,000 shares for $11.0M through a pre-arranged 10b5-1 trading plan. The sale represents a 100.0% reduction in his GMED holdings, reducing his post-transaction position to 0 shares. As this transaction was scheduled under a 10b5-1 plan rather than discretionary, the timing does not reflect independent judgment at the moment of sale. The complete exit by a then-CEO warrants close monitoring of the issuer's forward guidance, competitive positioning, and any contemporaneous changes in leadership or strategic direction.

Director Dan Lemaitre sells entire 14,375-share position at GMED for $1.2M; holds zero post-transaction.

Director Dan Lemaitre completed a complete exit of his GMED holdings through 2 separate sales on 2024-11-21 and 2024-11-22, selling 13,278 shares at $85.00 and 1,097 shares at $85.02 for a combined $1,221,893.21. The blended average price of $85.00 is just 0.5% below the 52-week high of $84.91, positioning this sale near peak valuation. His cross-ticker track record shows a 90-day well-timed rate of 0.00%, indicating his prior sells have not preceded declines; notably, his single prior sale at GMED on 2024-05-10 generated a positive 90-day return of +14.4%, suggesting the stock moved up after that earlier exit. The complete liquidation of a director's holdings warrants close observation of both the timing signal and any broader context around liquidity needs or confidence shifts, particularly given the company's elevated P/E of 126.10 and recent 90-day appreciation of +17.8%.

Director David D sold 40,000 GMED shares at $85.00 across 4 transactions for $3.4M on Nov 21-22.

David D, a director, executed 4 separate sales totaling 40,000 shares for $3,400,049.99 at an average price of $85.00, reducing his holdings by 19.4% from 205,967 shares to 165,967 shares. The timing is notable: the sales occurred within one day of the stock's 52-week high of $84.91, and the stock has since declined 0.5% to $84.49, suggesting the director sold near peak levels. His track record at GMED shows limited measurable outcomes on recent sales (two October sales with 30-day returns of +8.1% each, and a September sale with 0.2%), though his cross-ticker history spans 4 prior sells with an average 90-day return of +6.2% but a 0% well-timed rate (meaning his cross-ticker sells have generally been followed by stock appreciation, not declines). The multi-transaction structure and the magnitude (40K shares) indicate a deliberate execution, though the fundamental backdrop shows strong growth (revenue up 53.3% year-over-year) and sustained profitability of $51.8M, which may contextualize the sale within normal portfolio activity rather than distress signaling.

Scavilla Daniel T, then-CEO, sold 60,000 shares of GMED at $80.02 under 10b5-1 plan on 2024-11-06

Scavilla Daniel T, who was President and CEO at the time of this transaction, executed the complete liquidation of his 60,000 shares for $4,801,200.00 under a pre-arranged 10b5-1 trading plan. The transaction eliminated 100.0% of his reported holdings, reducing his position from 60,000 shares to 0 shares. Because the sale is part of a scheduled 10b5-1 plan rather than a discretionary trade, it reflects a predetermined trading schedule rather than a market-timing decision. The significance of a complete exit by the then-CEO warrants investor attention to whether this reflects a broader change in his relationship to the company or personal financial planning.